We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
The most recent trading session ended with Amgen (AMGN - Free Report) standing at $273.41, reflecting a -0.85% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a gain of 0.82% for the day. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq gained 1.77%.
Shares of the world's largest biotech drugmaker witnessed a loss of 7.73% over the previous month, trailing the performance of the Medical sector with its loss of 4.06% and the S&P 500's gain of 0.8%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. In that report, analysts expect Amgen to post earnings of $4.97 per share. This would mark year-over-year growth of 5.52%. Our most recent consensus estimate is calling for quarterly revenue of $8.82 billion, up 7.66% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $19.51 per share and a revenue of $33.16 billion, indicating changes of +4.61% and +17.65%, respectively, from the former year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.03% rise in the Zacks Consensus EPS estimate. Amgen is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Amgen is holding a Forward P/E ratio of 14.13. For comparison, its industry has an average Forward P/E of 24.46, which means Amgen is trading at a discount to the group.
We can also see that AMGN currently has a PEG ratio of 3.05. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.81.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 63, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Amgen (AMGN) Stock Sinks As Market Gains: Here's Why
The most recent trading session ended with Amgen (AMGN - Free Report) standing at $273.41, reflecting a -0.85% shift from the previouse trading day's closing. The stock fell short of the S&P 500, which registered a gain of 0.82% for the day. At the same time, the Dow lost 0.22%, and the tech-heavy Nasdaq gained 1.77%.
Shares of the world's largest biotech drugmaker witnessed a loss of 7.73% over the previous month, trailing the performance of the Medical sector with its loss of 4.06% and the S&P 500's gain of 0.8%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. In that report, analysts expect Amgen to post earnings of $4.97 per share. This would mark year-over-year growth of 5.52%. Our most recent consensus estimate is calling for quarterly revenue of $8.82 billion, up 7.66% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $19.51 per share and a revenue of $33.16 billion, indicating changes of +4.61% and +17.65%, respectively, from the former year.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.03% rise in the Zacks Consensus EPS estimate. Amgen is currently sporting a Zacks Rank of #3 (Hold).
Looking at its valuation, Amgen is holding a Forward P/E ratio of 14.13. For comparison, its industry has an average Forward P/E of 24.46, which means Amgen is trading at a discount to the group.
We can also see that AMGN currently has a PEG ratio of 3.05. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.81.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 63, which puts it in the top 26% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.